Last reviewed · How we verify
MenACWY-CRM197
MenACWY-CRM197 is a meningococcal conjugate vaccine that stimulates immune responses against serogroups A, C, W, and Y by conjugating polysaccharide antigens to a carrier protein (CRM197).
MenACWY-CRM197 is a meningococcal conjugate vaccine that stimulates immune responses against serogroups A, C, W, and Y by conjugating polysaccharide antigens to a carrier protein (CRM197). Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y.
At a glance
| Generic name | MenACWY-CRM197 |
|---|---|
| Sponsor | Novartis |
| Drug class | Meningococcal conjugate vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W, and Y, each conjugated to CRM197 (a non-toxic diphtheria toxin variant). This conjugation enhances immunogenicity by promoting T-cell dependent B-cell responses, resulting in improved antibody production and immunological memory compared to unconjugated polysaccharide vaccines.
Approved indications
- Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y
Common side effects
- Injection site pain/erythema
- Fever
- Myalgia
- Headache
Key clinical trials
- Meningococcal Serogroup ACYWX Conjugate Vaccine in Comparison With MenACWY-TT Conjugate Vaccine (PHASE3)
- Comparison of Two Meningococcal ACWY Conjugate Vaccines (PHASE2, PHASE3)
- Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults (PHASE2)
- Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination (PHASE3)
- Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Infant Study
- Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age. (PHASE3)
- Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life (PHASE3)
- Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MenACWY-CRM197 CI brief — competitive landscape report
- MenACWY-CRM197 updates RSS · CI watch RSS
- Novartis portfolio CI